FindTrial
Sign In

RGS5 regulates PD-L1 through the c-Myc/STAT3 pathway, thereby inhibiting immune cell infiltration and leading to resistance to immunotherapy in gastric cancer.

RGS5 regulates PD-L1 through the c-Myc/STAT3 pathway, thereby inhibiting immune cell infiltration and leading to resistance to immunotherapy in gastric cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115266
Enrollment
Unknown
Registered
2025-12-24
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

RGS5 low-expression group:none
RGS5 high-expression group:none

Sponsors

Huzhou Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. This study intends to conduct a retrospective investigation of gastric cancer cases confirmed by pathology from January 2015 to December 2024; 2. Participants aged 18-80 are included.

Exclusion criteria

Exclusion criteria: 1.Exclude the cases that were lost to follow-up

Design outcomes

Primary

MeasureTime frame
The expression level of RGS5 protein;—

Countries

China

Contacts

Public ContactZhenwei Yang

Huzhou Center Hospital

2780779862@qq.com+86 572 2023219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026